The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...
Scientists at the Leibniz Institute of Photonic Technology (Leibniz IPHT) have developed a new microarray-based diagnostic ...
The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...
"[People] had been developing Arabidopsis microarrays for a number of years, and these were some of the first papers that published high-quality data with real biological conclusions," says Chris Town ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...
The biochip market size is calculated at USD 14.37 billion in 2025 and is expected to reach around USD 42.15 billion by 2034, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback